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Background: The relationship between ischemic stroke (IS), diabetes mellitus (DM), and 
sex is intriguing. The aim of this study was to assess the effect modification of sex in the 
association between DM and short- and long-term disability and mortality in first-ever IS 
patients.
Methods: In a retrospective, observational, hospital-based study of a prospective series 
including first-ever IS patients from January 2006 until July 2011, differences in 3-month 
and 5-year mortality, and disability between diabetic and non-diabetic patients [modified 
Rankin Scale (mRS) from 3 to 5] were analyzed by sex.
results: In total, 933 patients (36.3% with DM, 50.5% women) were included. Overall 
3-month and 5-year mortality were 150 (16.1%) and 407 (44.1%), respectively. Adjusted 
for age, previous mRS, and stroke severity, patients with DM had significantly higher 
3-month disability [hazard ratio (HR): 1.49 (95% confidence interval (CI): 1.39–1.70), 
p < 0.0001], 5-year disability [HR: 1.41 (95% CI: 1.07–1.86), p = 0.015], and 5-year 
mortality [HR: 1.48 (95% CI: 1.20–1.81), p < 0.0001], compared with the non-DM group. 
Compared with non-DM women, women with diabetes had worse 3-month disability 
[HR: 1.81 (95% CI: 1.33–2.46), p < 0.0001] and 5-year mortality [HR: 1.72 (95% CI: 
1.30–2.20), p < 0.0001], and a trend for 5-year disability [HR: 1.40 (95% CI: 0.99–2.09), 
p = 0.057]. In men, DM had an effect on 3-month disability [HR: 1.45 (95% CI: 1.07–1.96), 
p = 0.018], a trend for 5-year disability [HR: 1.43 (95% CI: 0.94–2.19), p = 0.096], but no 
clear effect on 5-year mortality [HR: 1.22 (95% CI: 0.91–1.65), p = 0.186].
conclusion: Sex has a modifier effect on mortality in first-ever IS diabetic patients. 
Long-term mortality is increased in diabetic women compared with non-diabetic women, 
a difference not observed in men.
Keywords: ischemic stroke, diabetes, sex differences, outcome, mortality
inTrODUcTiOn
Diabetes mellitus (DM) is an independent risk factor for stroke and cardiovascular disease (1). 
Patients with DM have up to threefold increased risk of recurrent stroke, compared with those 
with normal glucose levels (2, 3). Additionally, DM raises ischemic stroke (IS) severity, and has 
been associated with a poor functional outcome, worse long-term vascular prognosis, and increased 
mortality after stroke onset, compared with non-diabetic patients (4–6). Some studies have associ-
ated glycemic values with the poor short-term outcome, concluding that high-glycemia levels during 
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acute IS, but not DM diagnosis, increased the odds for poor 
30-day to 3-month outcome (7–9).
The relationship between IS, DM, and sex is intriguing. A 
recent meta-analysis has estimated that women with DM have 
a 27% greater risk of stroke than men with DM (10), and some 
studies suggest that they have worse survival and functional 
outcome than men (11–14). Other studies, however, have found 
increased mortality for both women and men with diabetes (15), 
a time-dependent mortality risk only for DM men (16), and lower 
adjusted mortality in DM women than in men (17) The reasons 
for these sex differences are unknown, and the majority of the 
research has focused on comparing men and women with DM, 
with little information about how sex can influence the short- and 
long-term impact of DM on post-IS prognosis. On the other hand, 
many of these studies are unadjusted (12, 17) or adjusted only 
by age and vascular risk factors (14–17) or previous treatments 
(15, 16) without taking into account two of the most important 
predictors of mortality: previous disability and stroke severity.
The aim of this study was to assess the effect modification of 
sex in the association between DM and short- and long-term 
disability and mortality in first-ever IS patients, as a primary 
end-point. We also sought to analyze, as a secondary end-point, 
whether differences exist between DM and non-DM patients 
in acute stroke management and cardiovascular events during 
5-year follow-up.
MaTerials anD MeThODs
The study was a retrospective analysis of a prospective hospital-
based stroke register. From January 2006 through July 2011, 1,542 
patients with a first-ever IS were admitted to our hospital. Patients 
with previous modified Rankin Scale (mRS) >3, transient 
ischemic attack, missing follow-up data, inaccurate or incomplete 
clinical information, unusual cause of stroke, residence outside 
our hospital reference area, or those who refused to participate in 
the BASICMAR database (n = 8) were excluded. The BASICMAR 
database (18) is an ongoing prospective register of patients with 
acute stroke at University Hospital del Mar, a tertiary public 
hospital serving a population of 330,000 in three districts of the 
city of Barcelona. The final cohort was 933 patients.
All included patients received a computed tomography (CT) 
scan in the emergency room and were evaluated at hospital 
admission by a vascular-trained neurologist who established 
initial severity using the National Institute of Health Stroke Scale 
(NIHSS). Stroke subtype was categorized using the TOAST clas-
sification (19). Additional CT, MRI evaluations, or angiographic 
studies were done, as needed, during hospitalization. HbA1c 
was measured during hospital admission in 300 of 339 diabetic 
patients (88.5%).
Vascular risk factors, as defined by international guidelines, 
were obtained from the patient, relatives, caregivers, or previous 
medical records after stroke onset. A structured questionnaire was 
used to record the following variables: arterial hypertension (evi-
dence of at least two raised blood pressure measurements, systolic 
>140 mmHg or diastolic >90 mmHg, recorded on different days 
before stroke onset; a physician’s diagnosis; or use of medication); 
diabetes (previous physician diagnosis or use of medication); 
hyperlipidemia (physician diagnosis, use of medication, serum 
cholesterol concentration >220 mg/dL, low-density lipoprotein 
cholesterol >130  mg/dL, or serum triglyceride concentration 
>150 mg/dL); ischemic heart disease (IHD) (documented history 
of angina pectoris or myocardial infarction); peripheral arterial 
disease (PAD) (documented current intermittent claudication 
with an ankle brachial index <0.9 or a history of intermittent 
claudication, together with a previous related intervention, such 
as amputation); atrial fibrillation (AF) (physician diagnosis, use 
of medication, or conclusive electrocardiogram data); current 
smoking habit; alcohol overuse (>60 g/day); and illicit drug use. 
Atherosclerosis burden was calculated as previously described 
(20), assigning a score of 0 to patients with no previous diagnosis 
of IHD or PAD, 1 to a diagnosis of IHD or PAD, and 2 to patients 
with the concomitant presence of both diseases. For DM patients, 
the usual pre-stroke treatment for DM was recorded.
Under national and international guidelines, treatment 
included recombinant tissue plasminogen activator (rtPA) (first 
4.5  h) and endovascular therapy (21). During hospitalization, 
additional glucose testing and HbA1C were done by systematic 
protocol, when indicated; new DM cases were determined at 
discharge.
The primary end-points were mortality and functional 
outcome at 3-month and 5-year follow-up. The secondary end-
points were: (a) acute stroke care (admission to a monitored acute 
care stroke unit, intravenous rtPA treatment or endovascular 
thombectomy) and (b) new vascular events, including stroke, 
intracranial hemorrhage, coronary artery disease (CAD), and 
cardiovascular death, recorded at 5-year follow-up, along with 
the detection of any previously unknown AF. Mortality and dis-
ability data, vascular recurrences, and the detection of previously 
non-diagnosed AF were obtained from a clinic visit at 3-month 
and 5-year follow-up, from electronic medical records, hospital 
admissions records, or by telephone contact with primary care 
physicians.
statistical analysis
Age and NIHSS score had a non-normal distribution and were 
expressed as medians and interquartile ranges (IQR). Categorical 
data were expressed as counts and percentages. Differences 
in parametric and non-parametric continuous variables were 
evaluated using the t-test and Mann–Whitney U test, respectively, 
and the χ2 test was used for proportional analysis. We compared 
by bivariate analysis the demographic, vascular risk, and stroke 
care differences between: (1) DM and non-DM patients; (2) DM 
women vs non-DM women, and (3) DM men vs non-DM men.
Three-month and 5-year disability and mortality were 
compared with test differences in prognosis between DM and 
non-DM patients, and stratified by sex. To analyze the interac-
tion of sex and diabetes, bivariate, and Cox regression analyses 
adjusted for age, previous mRS, and NIHSS score at admission 
were performed for both men and women to assess 3-month and 
5-year disability and 5-year mortality by sex. The effect modifica-
tion of sex was tested using interactions (diabetes-sex) in the 
models. For the secondary end-points, we compared the number 
of patients admitted to monitored acute care stroke unit and the 
number of patients treated with intravenous rtPA or mechanical 
TaBle 1 | Differences between diabetic and non-diabetic patients.
Total  
(n = 933)
DM (n = 339) non-DM 
(n = 594)
Unadjusted  
hr (95% ci)
p-Value adjusteda  
hr (95% ci)
p-Value
Demographic and vascular risk factors
Age, years, median (IQR) 77 (68–83) 76 (68–82) 78 (68–84) 0.056
Sex, female, n (%) 471 (50.5) 162 (47.8) 309 (52.0) 0.221
Hypertension, n (%) 669 (71.9) 269 (79.6) 400 (67.6) 1.87 (1.37–2.57) 0.0001
Hyperlipidemia, n (%) 387 (41.7) 174 (51.8) 213 (36.0) 1.91 (1.46–2.51) 0.0001
Atrial fibrillation, n (%) 329 (35.3) 117 (34.5) 212 (35.7) 0.722
Coronary artery disease, n (%) 143 (15.4) 72 (21.4) 61 (12.0) 1.99 (1.39–2.86) 0.0001
Peripheral arterial disease, n (%) 79 (8.5) 40 (11.9) 39 (6.6) 1.92 (1.21–3.05) 0.007
Smoking, n (%) 184 (20.1) 55 (16.6) 129 (22.1) 0.70 (0.49–0.99) 0.048
Alcohol overuse, n (%) 168 (18.4) 61 (18.5) 107 (18.4) 1.0
Previous disability, median (IQR) 0(0–0) 0 (0–1) 0 (0–0) 0.0001
stroke characteristic and acute treatment data
NIHSS points, median (IQR) 5 (3–13) 5 (3–11) 6 (3–14) 0.070
Atherothrombotic stroke, n (%) 131 (14.9) 61 (18.0) 70 (11.8)
Lacunar stroke, n (%) 217 (23.3) 79 (23.3) 138 (23.2) 0.047
Cardioembolic stroke, n (%) 345 (37.0) 122 (36.0) 223 (37.5)
Stroke of undetermined causeb, n (%) 240 (25.7) 77 (22.7) 163 (27.4)
NIHSS points, median (IQR) 5 (3–13) 5 (3–11) 6 (3–14) 0.070
rtPA treatment 162 45 (13.3) 117(19.7) 0.62 (0.43–0.91) 0.015 1.01 (0.71–1.44) 0.963
Endovascular or rtPA treatment 175 50 (14.7) 125 (21.0) 0.65 (0.45–0.939) 0.019 1.06 (0.75–1.48) 0.756
Outcome measures
New atrial fibrillationc, n (%) 58 (10.1) 13 (6.0) 45 (12.5) 0.47 (0.25–0.89) 0.017 0.62 (0.33–1.16) 0.135
Total cardiovascular events, n (%) 290 (31.8) 124 (37.3) 166 (28.6) 1.49 (1.12–1.98) 0.006 1.50 (1.18–1.90) 0.001
Stroke recurrence, n (%) 141(15.5) 57 (17.2) 84 (14.5) 1.22 (0.85–1.77) 0.280
Coronary artery disease, n (%) 47 (5.2) 20 (6.0) 27 (4.7) 1.31 (0.72–2.38) 0.368
Peripheral arterial disease, n (%) 64 (7.0) 31 (9.3) 33 (5,7) 1.71 (1.03–2.84) 0.043 1.76 (1.07–2.90) 0.026
Intracranial hemorrhage, n (%) 19 (2.1) 7 (2.1) 12 (2.1) 1.02 (0.40–2.62) 0.968
Cardiovascular death, n (%) 27 (3.0) 14 (4.2) 13 (2.2) 1.92 (0.89–4.13) 0.091 2.19 (1.01–4.72) 0.046
3-month mortality, n (%) 150 (16.1) 55 (16.2) 95 (16.0) 1.02 (0.71–1.46) 0.926 1.13 (0.81–1.58) 0.479
3-month disability, n (%) 360 (43.0) 151 (50.0) 209 (39.0) 1.57 (1.18–2.08) 0.002 1.49 (1.39–1.70) 0.0001
5-year mortality, n (%) 407 (43.6) 170 (50.7) 237 (40.4) 1.52 (1.16–1.99) 0.002 1.48 (1.20–1.81) 0.0001
5-year disability, n (%) 219 (50.5) 89 (61.0) 130 (45.1) 1.90 (1.27–2.85) 0.002 1.41 (1.07–1.86) 0.015
aAdjusted for age, previous functional disability (by modified Rankin Scale), and stroke severity (by National Institute of Health Stroke Scale).
bStroke of undetermined cause includes unknown cause, more than one possible cause, or insufficient study.
cNew atrial fibrillation = diagnoses of atrial fibrillation during 5-year follow-up.
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thrombectomy between diabetic and non-diabetic women, and 
diabetic and non-diabetic men.
The hazard ratios (HRs) were presented with 95% confidence 
intervals (CIs). The significance level was set at 0.05. All analyses 
were two-tailed and performed with the SPSS statistical package 
or Stata 12 package.
Standard Protocol Approvals, Registrations, and Patient 
Consents: The information used in this study was collected from 
the prospective BASICMAR register, with the approval of our 
local ethics committee (CEIC-Parc de Salut Mar). All patients 
gave their informed consent prior to their inclusion in the study.
resUlTs
A total of 933 patients were included in the analysis. We 
excluded 609 patients for the following reasons, according to the 
established criteria: previous poor functional status (mRS > 3), 
102; transient ischemic attack, 206; missing follow-up data, 19; 
inaccurate or incomplete clinical information, 29; unusual cause 
of stroke, 42; residence outside our hospital reference area, 203; 
and declined participation in the BASICMAR database, 8. There 
was no difference between the excluded and included patients in 
the percentage of DM cases (9.7 vs 9.8%, respectively). However, 
excluded patients were older [82.7 (9.5) vs 72.9 (12.6) years, 
p < 0.001], more likely to be women (13.5 vs 6.3%, p < 0.0001), 
and had more severe strokes (p > 0.0001), AF (p = 0.002), and 
IHD (p = 0.001), compared with included patients. Baseline char-
acteristics of the study population are shown in Table 1. Missing 
data included history of PAD (n  =  2), arterial hypertension 
(n = 3), hyperlipidemia (n = 5), atherosclerotic burden (n = 6), 
data on stroke unit admission (n = 9), smoking (n = 18), overuse 
of alcohol (n = 20), new cardiovascular events during follow-up 
(n = 21), new AF during follow-up (n = 28), 5-year mRS (n = 85), 
and mortality (n = 10). Patients with missing follow-up data were 
older than those with complete data [75.0 (12.1) vs 70.0 (11.6) 
years, p < 0.0001]; there were no differences in sex, previous mRS, 
risk factors (hypertension, DM, hyperlipidemia, AF, PAD, CAD, 
smoking, and alcohol intake) and stroke severity.
Overall, 339 (36.3%) patients had DM. HbA1c during admis-
sion was available in 300/339 (88.5%) diabetic patients, 145/162 
(89.5%) women, and 155/177 (87.6%) men. Median HbA1c 
(IQR) was 7.1 (6.5–8.2) for diabetic women and 7.5 (6.6–9.0) for 
diabetic men, p = 0.051. Regarding diabetes treatment previous 
to stroke, 186 (54.9%) patients were taking oral antidiabetics 
TaBle 2 | Differences between diabetic and non-diabetic women and diabetic and non-diabetic men.
Total DM non-DM Unadjusted hr (95% ci) p-Value adjusteda hr (95% ci) p-Value
Women (n = 471) (n = 162) (n = 309)
Demographic and vascular risk factors
Age, years, median (IQR) 80 (73–85) 79 (73–84) 80 (73–86) 0.635
Hypertension, n (%) 369 (78.7) 137 (85.1) 232 (75.3) 1.87 (1.13–3.10) 0.017
Hyperlipidemia, n (%) 201 (42.9) 89 (54.9) 112 (36.5) 2.12 (1.44–3.13) 0.0001
Atrial fibrillation, n (%) 225 (46.8) 81 (50.0) 144 (46.6) 1.14 (0.78–1.68) 0.498
Coronary artery disease, n (%) 62 (13.2) 36 (22.4) 26 (8.4) 3.12 (1.81–5.40) 0.0001
Peripheral arterial disease, n (%) 20 (4.3) 8 (5.09) 12 (3.9) 1.29 (0.52–3.23) 0.632
Smoking, n (%) 30 (6.5) 5 (3.1) 25 (8.3) 0.35 (0.13–0.94) 0.030
Alcohol overuse, n (%) 26 (5.6) 10 (6.3) 16 (5.3) 1.19 (0.53–2.68) 0.676
Previous disability, median (IQR) 0 (0–2) 0 (0–1) 0 (0–0) 0.0001
Atherosclerotic burden, median (IQR) 0 (0–0) 0 (0–1) 0 (0–0) 0.0001
stroke characteristic and acute treatment data
NIHSS points, median (IQR) 7 (4–16) 7 (3–17) 7 (4–16) 0.963
Atherothrombotic stroke, n (%) 41 (8.7) 16 (9.9) 25 (8.1)
Lacunar stroke, n (%) 75 (15.9) 23 (14.2) 52 (16.8) 0.830
Cardioembolic stroke, n (%) 232 (49.3) 81 (50.0) 151 (48.9)
Stroke of undetermined cause, n (%) 123 (26.1) 42 (25.9) 81 (26.2)
rtPA treatment 85 (18.0) 25 (15.4) 60 (19.4) 0.76 (0.45–1.26) 0.315
rtPA/endovascular treatment, n (%) 95 (20.2) 28 (17.3) 67 (21.7) 0.76 (0.46–1.23) 0.279
Stroke unit admission, n (%) 390 (83.3) 128 (79.5) 262 (85.3) 0.67 (0.41–1.09) 0.118
Outcome measures
New atrial fibrillationb, n (%) 34 (7.3) 7 (4.3) 27 (8.9) 0.47 (0.20–1.09) 0.092
Total cardiovascular events, n (%) 128 (27.6) 51 (32.1) 77 (25.3) 1.39 (0.91–2.12) 0.127
Stroke recurrence, n (%) 67 (14.5) 27 (17.0) 40 (13.2) 1.35 (0.79–2.30) 0.267
Coronary artery disease, n (%) 19 (4.1) 10 (6.3) 9 (3.0) 2.20 (0.88–5.53) 0.086
Peripheral arterial disease, n (%) 26 (5.6) 11 (6.9) 15 (4.9) 1.43 (0.64–3.20) 0.399 1.63 (073–3.64) 0.235
Intracranial hemorrhage, n (%) 9 (1.9) 2 (1.3) 7 (2.3) 0.54 (0.11–2.63) 0.439
Cardiovascular death, n (%) 13 (2.8) 8 (5.0) 5 (1.7) 3.15 (1.02–9.82) 0.037 3.76 (1.18–12.0) 0.025
Men (n = 462) (n = 177) (n = 285)
Demographic and vascular risk factors
Age, years, median (IQR) 73 (64–81) 72 (64–79) 75 (64–82) 0.083
Hypertension, n (%) 300 (65.1) 132 (74.6) 168 (59.2) 2.03 (1.34–3.06) 0.001
Hyperlipidemia, n (%) 186 (40.5) 85 (48.9) 101 (35.4) 1.74 (1.19–2.55) 0.006
Atrial fibrillation, n (%) 104 (22.5) 36 (20.3) 68 (23.9) 0.82 (0.52–1.29) 0.423
Coronary artery disease, n (%) 81 (17.6) 36 (20.5) 45 (15.8) 1.37 (0.84–2.22) 0.211
Peripheral arterial disease, n (%) 59 (12.8) 32 (18.2) 27 (9.5) 2.12 (1.22–3.69) 0.009
Smoking, n (%) 154 (33.9) 50 (29.2) 104 (36.7) 0.71 (0.47–1.07) 0.125
Alcohol overuse, n (%) 142 (31.4) 51 (30.0) 91 (32.3) 0.90 (0.60–1.36) 0.676
Previous disability, median (IQR) 0 (0–0) 0 (0–1) 0 (0–0) 0.112
Atherosclerotic burden, median (IQR) 0 (0–1) 0 (0–1) 0 (0–0) 0.009
stroke characteristic and acute treatment data
NIHSS points, median (IQR) 5 (2–9) 4 (2–6) 5 (2–12) 0.068
Atherothrombotic stroke, n (%) 90 (19.5) 45 (25.4) 45 (15.9)
Lacunar stroke, n (%) 142 (30.7) 56 (31.6) 86 (30.2)
Cardioembolic stroke, n (%) 113 (24.5) 41 (23.2) 72 (25.3) 0.030
Stroke of undetermined causec, n (%) 117 (25.3) 35 (19.8) 82 (29.8)
rtPA treatment 77 (16.7) 20 (11.3) 57 (20.0) 0.51 (0.29–0.88) 0.015
rtPA/endovascular treatment, n (%) 81 (17.5) 22 (12.4) 95 (20.7) 0.54 (0.32–0.92) 0.024
Stroke unit admission, n (%) 402 (88.2) 154 (88.0) 248 (88.3) 0.98 (0.55–1.75) 1
Outcome measures
New atrial fibrillationb, n (%) 24 (5.5) 6 (3.5) 18 (6.8) 0.50 (0.19–1.28) 0.197
Total cardiovascular events, n (%) 162 (36.1) 73 (42.2) 89 (32.2) 1.39 (0.91–2.12) 0.034 1.34 (0.98–1.83) 0.065
Stroke recurrence, n (%) 74 (16.5) 30 (17.3) 44 (15.9) 1.11 (0.67–1.84) 0.697
Coronary artery disease, n (%) 28 (6.2) 10 (5.8) 18 (6.5) 0.88 (0.40–1.95) 0.752
Peripheral arterial disease, n (%) 38 (8.5) 20 (11.6) 18 (6.5) 1.87 (0.96–3.65) 0.081 1.73 (0.91–2.29) 0.093
Intracranial hemorrhage, n (%) 10 (2.2) 5 (2.9) 5 (1.8) 1.61 (0.46–5.66) 0.518
Cardiovascular death, n (%) 14 (3.1) 6 (3.5) 8 (2.9) 1.20 (0.41–3.53) 0.784
aAdjusted for age, previous functional disability (by modified Rankin Scale), and stroke severity (by National Institute of Health Stroke Scale).
bNew atrial fibrillation (AF) = diagnoses of AF during 5-year follow-up.
cStroke of undetermined cause includes unknown cause, more than one possible cause, or insufficient study.
4
Soriano-Reixach et al. Sex, Diabetes, and Outcome in IS
Frontiers in Neurology | www.frontiersin.org April 2018 | Volume 9 | Article 250
TaBle 3 | Outcome parameters comparing diabetic women with non-diabetic women and diabetic men with non-diabetic men.
DM non-DM Unadjusted hr (95% ci) p-Value adjusteda hr (95% ci) p-Value
Women
3-month disability, n (%) 77 (61.6) 103 (41.0) 2.31 (1.49–3.58) 0.0001 1.81 (1.33–2.46) 0.0001
5-year disability, n (%) 48 (78.7) 83 (54.6) 3.07 (1.54–6.13) 0.001 1.40 (0.99–2.09) 0.057
5-year mortality, n (%) 96 (59.3) 121 (39.4) 2.24 (1.52–3.30) 0.0001 1.72 (1.30–2.20) 0.0001
Men
3-month disability, n (%) 74 (41.8.2) 106 (37.2) 1.21 (0.83–1.78) 0.323 1.45 (1.07–1.96) 0.018
5-year disability, n (%) 41 (48.2) 47 (34.6) 1.77 (1.02–3.07) 0.049 1.43 (0.94–2.19) 0.096
5-year mortality, n (%) 74 (42.8) 116 (41.4) 1.06 (0.72–1.55) 0.845 1.22 (0.91–1.65) 0.186
DM:sex interactionb
3-month disability 0.0186
5-year disability 0.0049
5-year mortality 0.0001
aAdjusted by age, previous functional disability (by modified Rankin Scale), and stroke severity (by National Institute of Health Stroke Scale).
bp-Values obtained through Wald Test.
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[88/162 women (54.3%), and 98/177 (55.4%) men, p = 0.847; and 
75 (22.1%) were under insulin treatment, 39/162 women (24.1%) 
and 36/177 men (20.3%), p = 0.408].
Table 1 shows that patients with DM had more vascular risk 
factors, worse previous functional status, and received less rtPA 
treatment than non-DM patients. Atherothrombotic stroke 
was more frequent in DM (18.0%) than in non-DM patients 
(11.8%), p =  0.047. During the 5-year follow-up, DM patients 
were more likely to have a cardiovascular event than non-DM 
patients (HR: 1.42, 95% CI: 1.06–1.91; adjusted p = 0.019), with 
PAD being the only event subtype that differed significantly 
between the two groups (HR: 1.81, 95% CI: 1.18–2.76; adjusted 
p = 0.006). In contrast, new AF was detected more frequently in 
non-DM than in DM patients (p =  0.026). At 3 months, there 
were no mortality differences between DM and non-DM patients 
(adjusted p = 0.466). However, unadjusted and adjusted 3-month, 
and 5-year disability, and 5-year mortality, were greater in DM 
than in non-DM patients (adjusted HR: 1.49, 95% CI: 1.39–1.70, 
p <  0.0001; adjusted HR: 1.41, 95% CI: 1.07–1.86, p <  0.015; 
adjusted HR: 1.48, 95% CI: 1.20–1.81, p < 0.0001; respectively).
Table  2 shows the differences between DM and non-DM 
women and DM and non-DM men. Diabetic women had more 
vascular risk factors, more previous disability, more atheroscle-
rotic burden, and less current smoking than non-DM women. 
There were no differences in stroke etiology between DM and 
non-DM women (p  =  0.830). Men with diabetes had more 
vascular risk factors than non-diabetic patients in general, and 
were less likely to receive acute reperfusion treatments. After 
adjustment, however, this difference disappeared. There were 
more atherothrombotic strokes (25.4%) and fewer strokes with 
undetermined cause (19.8%) in DM men compared with non-
DM men (15.9 and 29.8%, respectively, p = 0.030).
Primary end-Points
Women with diabetes showed higher 3-month disability (adjusted 
HR: 1.81, 95% CI: 1.33–2.46, p < 0.0001), and 5-year mortality 
(adjusted HR: 1.72, 95% CI: 1.30–2.20, p < 0.0001), and a trend 
for 5-year disability (adjusted HR: 1.40, 95% CI: 0.99–2.09, 
p = 0.057), compared with non-DM women (Table 3). In men, 
DM had an effect on 3-month disability (adjusted HR: 1.45, 95% 
CI: 1.07–1.96, p = 0.018), a trend for 5-year disability (adjusted 
HR: 1.43, 95% CI: 0.94–2.19, p = 0.096), but no effect on 5-year 
mortality (adjusted HR: 1.22, 95% CI: 0.91–1.65, p =  0.186). 
Table 3 also shows the results of the interaction analyses between 
DM and sex.
Cox survival curves adjusted for age, stroke severity (NIHSS), 
and previous mRS are shown in Figure  1. Figure  1A shows 
that patients with diabetes had higher 5-year mortality than 
non-DM patients (HR: 1.49, 95% CI: 1.22–1.82, p <  0.0001). 
Figure  1B shows that women with diabetes had significantly 
higher 5-year mortality than non-DM women (HR: 1.74, 95% 
CI: 1.32–2.31, p < 0.0001). Figure 1B shows that in men, DM 
had no effect on 5-year mortality (HR: 1.23, 95% CI: 0.91–1.66, 
p = 0.173).
secondary end-Points
No differences were observed between women with and with-
out DM or between men with and without DM in the variables 
related to acute stroke care: stroke unit admission, intravenous 
rtPA treatment, and endovascular thrombectomy (Table  2). 
Regarding cardiovascular events during follow-up, although 
no difference in total cardiovascular events was observed, 
women with DM had higher cardiovascular-specific mortality, 
compared with non-DM women (adjusted HR: 3.76, 95% CI: 
1.18–12.0, p =  0.025). For men, there was a trend of higher 
cardiovascular events (HR: 1.34, 95% CI: 0.98–1.83, p = 0.065) 
and a trend of higher new PAD during follow-up in DM com-
pared with non-DM (adjusted HR: 1.73, 95% CI: 0.91–2.29, 
p = 0.093).
DiscUssiOn
The main finding of our study was that diabetes has a sex-related 
modifier effect on IS outcomes: women with DM had higher 
5-year mortality compared with women without diabetes, but 
this effect was not significant in men.
The demographic differences between diabetic and non-
diabetic patients observed in our study are consistent with the 
literature (13, 22, 23). Diabetic patients were older and had more 
vascular risk factors, such as hypertension, hyperlipidemia, 
FigUre 1 | Survival curves using Cox regression analysis adjusted for age, stroke severity (National Institute of Health Stroke Scale), and previous modified Rankin 
Scale score. (a) Compares 5-year survival between diabetic and non-diabetic patients. (B) Compares 5-year survival between diabetic and non-diabetic women. 
(c) Compares 5-year survival between diabetic and non-diabetic men.
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coronary, and PADs, and worse previous functional status. 
Regarding the interaction of sex and diabetes, women with 
diabetes had more vascular risk factors, more previous dis-
ability, more atherosclerotic burden, less current smoking, and 
higher cardiovascular-specific mortality, compared with non-
DM women. Men with diabetes had more vascular risk factors 
and a trend of new cardiovascular events, especially new PAD 
during follow-up, compared with non-diabetic patients. As in 
some previous studies, we observed no DM effect on short-term 
mortality (6, 24, 25); however, DM was an independent risk 
factor for long-term mortality for the whole series (before sex 
interaction analyses). Moreover, diabetic stroke survivors had 
greater probability of disability at 3  months and at 5  years, 
compared with non-DM patients, results similar to some 
previous reports (25). In our analysis, we found that patients 
with diabetes had a 5-year cumulative cardiovascular event 
rate of 37.3%, higher than in non-diabetics. The 5-year stroke 
recurrence rate in DM patients was 17.2%, similar to a previous 
meta-analysis (26).
Regarding the primary end-points of the study, the differences 
in the outcome measures between women with and without DM 
and men with and without DM support a sex-related modifier 
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effect on IS outcomes in DM patients suggesting a different role of 
DM in men, compared with women. There was a special effect on 
long-term mortality, where DM had a deleterious effect in women 
but only a slight trend in men. Our study was adjusted for the 
three most powerful variables associated with stroke death: age, 
previous disability, and stroke severity. This reinforces previous 
studies showing deleterious effects of DM in women with IS 
(11–14). Our results differ from a German IS study that found 
no DM-related mortality differences for women but diabetic 
men with IS had lower short-term mortality, compared with 
non-diabetic men; notably, this effect did not persist after a year 
(16). A recent Canadian study showed lower mortality in DM 
women (17). However, neither study adjusted for stroke severity 
and disability previous to the index stroke.
The reason for the greater deleterious effect of DM on 
outcome we observed in women, compared with men, is 
unknown. It is well accepted that women have worse outcome 
than men after IS (27). Some researchers have reported that 
women are in worse condition than men at the time of new 
DM diagnosis, presenting with greater endothelial dysfunc-
tion and more severe hypertension due to underdetection 
and undertreatment of diabetes (10, 28). The inflammatory 
effect of diabetes has been established, along with its greater 
importance as a risk factor for stroke in women (3, 29, 30) 
and aggravates brain damage from stroke (31), compared with 
men. Other risk factors mainly affecting women have been 
described, such as relative longevity and sex-specific immune 
response and hormones (32, 33). Lower estrogen levels in 
postmenopausal women reduce the anti-inflammatory and 
neuroprotective effects of the hormone (34). Therefore, the 
high-inflammatory environment produced by diabetes, 
combined with lower neuroprotection from estrogens, may 
aggravate brain damage, and consequently increase morbid-
ity and mortality outcomes in women with diabetes. Further 
studies in this direction might help to reveal the etiology of 
these differences in outcomes.
Regarding the study’s secondary end-point, and in order to 
search for a mechanism that could explain the higher mortality 
in DM than non-DM patients, we analyzed whether differences in 
acute care or acute treatment between these patient groups exist, 
with negative result. We also did not find higher stroke recurrence 
in the DM group, but a significant increase in cardiovascular 
death was observed, compared with non-DM women. Again, this 
could suggest a specific, sex-related, deleterious effect of diabetes 
for women with IS. However, the fact that we had not found these 
differences in DM compared with non-DM men, also raises the 
question of other factors more related to gender that could have 
had influence in the results (i.e., chronic conditions such as dia-
betes are differently addressed in women than men by physicians, 
and have a different self-management impact) (35). Regarding 
the controversy about whether women have worse DM control 
than men that could explain a worse outcome in DM patients 
(36, 37), our study analyzed DM control (by HbA1c levels previ-
ous to IS), finding a non-significant trend for a better control in 
women than in men (p = 0.051). In our study, patients with high-
previous disability were excluded (102 cases, 69 women, and 33 
men) because one of our aims was to analyze the effect of DM on 
functional outcome after IS. We believe that the eventual impact 
on the end-points of the study due to the exclusion of these cases 
is small, because the percentage of DM patients was quite similar 
between excluded women and men (34.8 vs 36.4%, p =  0.827) 
and between all cases excluded due to previous disability and all 
included patients (35.3 vs 36.3%, p = 0.739).
limitations
The present study has several limitations. The first potential bias is 
due to the single-center design. However, stroke care in Catalonia 
is very homogeneous, and the organization of the stroke code 
ensures that the vast majority of acute IS cases in our catchment 
area are referred to our hospital with no bias. Moreover, cases 
from other healthcare service areas were excluded. Second, 
cardiovascular recurrences and new AF diagnoses were assessed 
retrospectively. However, as all patients were from our catch-
ment area, in most cases we could review their medical reports 
or contact the patient or medical practitioner. Third, the mRS 
was used to evaluate disability but, in some cases, this was done 
by telephone or by examining medical reports. Fourth, we did 
not have complete data on all causes of death during the 5-year 
follow-up. Our study also has strengths, because the cohort was 
quite large and well characterized, with complete baseline clinical 
data and follow-up that, despite being retrospective, was done 
with minimal losses to follow-up.
cOnclUsiOn
Our study showed that diabetes remarkably increases the prob-
ability of both death and disability in IS patients, and supported a 
sex-related modifier effect on IS outcomes, as the worst outcome 
was observed only in women with diabetes. The explanation 
of this greater deleterious effect of diabetes on women with IS 
remains to be elucidated.
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